PROCEPT BioRobotics CorpPRCTEarnings & Financial Report
PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.
Revenue
$68.2M
Gross Profit
$43.7M
Operating Profit
$-19.7M
Net Profit
$-18.9M
Gross Margin
64.0%
Operating Margin
-28.9%
Net Margin
-27.6%
YoY Growth
56.6%
EPS
$-0.34
PROCEPT BioRobotics Corp Q4 FY2024 Financial Summary
PROCEPT BioRobotics Corp reported revenue of $68.2M (up 56.6% YoY) for Q4 FY2024, with a net profit of $-18.9M (up 31.4% YoY) (-27.6% margin). Cost of goods sold was $24.6M, operating expenses totaled $63.4M.
Key Financial Metrics
| Total Revenue | $68.2M |
|---|---|
| Net Profit | $-18.9M |
| Gross Margin | 64.0% |
| Operating Margin | -28.9% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
PROCEPT BioRobotics Corp Q4 FY2024 revenue of $68.2M breaks down across 3 segments, led by Other at $32.9M (48.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $32.9M | 48.2% |
| Outside The United States | $24.0M | 35.2% |
| Service Revenue | $11.3M | 16.6% |
PROCEPT BioRobotics Corp Revenue by Segment — Quarterly Trend
PROCEPT BioRobotics Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Outside The United States) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Other | $11.1M | $9.8M | — | — |
| Outside The United States | — | — | $9.4M | $9.6M |
| Service Revenue | — | $5.0M | $4.8M | $4.4M |
PROCEPT BioRobotics Corp Annual Revenue by Year
PROCEPT BioRobotics Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $308.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $308.1M |
| 2024 | $224.5M |
| 2023 | $136.2M |
| 2022 | $75.0M |
PROCEPT BioRobotics Corp Quarterly Revenue & Net Profit History
PROCEPT BioRobotics Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $83.1M | +20.2% | $-31.6M | -38.1% |
| Q4 FY2025 | $76.4M | +11.9% | $-29.8M | -39.1% |
| Q3 FY2025 | $83.3M | +42.8% | $-21.4M | -25.7% |
| Q2 FY2025 | $79.2M | +48.4% | $-19.6M | -24.7% |
| Q1 FY2025 | $69.2M | +55.3% | $-24.7M | -35.8% |
| Q4 FY2024 | $68.2M | +56.6% | $-18.9M | -27.6% |
| Q3 FY2024 | $58.4M | +66.3% | $-21.0M | -35.9% |
| Q2 FY2024 | $53.4M | +61.2% | $-25.6M | -48.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.4M | $58.4M | $68.2M | $69.2M | $79.2M | $83.3M | $76.4M | $83.1M |
| YoY Growth | 61.2% | 66.3% | 56.6% | 55.3% | 48.4% | 42.8% | 11.9% | 20.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $374.4M | $374.1M | $534.0M | $519.4M | $513.1M | $511.5M | $508.1M | $487.1M |
| Liabilities | $122.6M | $132.9M | $131.8M | $130.2M | $127.3M | $131.3M | $142.2M | $139.4M |
| Equity | $251.8M | $241.2M | $402.2M | $389.2M | $385.8M | $380.3M | $365.9M | $347.7M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-15.7M | $-18.8M | $-32.4M | $-17.0M | $-15.0M | $-6.6M | $-10.3M |